Pharma | Med Herald

0 0

Biogen to acquire RayThera in deal worth up to $1 billion

The acquisition adds multiple immunology assets to Biogen’s pipeline, including a lead anti-inflammatory candidate expected to enter Phase 1 development…

editorial4 days ago

0 0

FDA approves Utebzi, first oral carbapenem antibiotic for complicated urinary tract infections in adults

New oral treatment could help eligible patients receive care outside hospital settings instead of relying on intravenous antibiotics The US…

editorial6 days ago

0 0

FDA approves first hyaluronic acid injectable to reduce horizontal neck lines

The U.S. Food and Drug Administration (FDA) has approved SKINVIVE by Juvéderm for reducing horizontal neck lines and improving neck…

editorial1 week ago

0 0

KEYTRUDA-WELIREG combination wins FDA approval for high-risk kidney cancer after surgery

Approval is based on Phase III LITESPARK-022 trial results showing a 28% reduction in the risk of disease recurrence, metastasis…

editorial2 weeks ago

0 0

CagriSema shows strong blood sugar and weight loss results in phase 3 diabetes trials

Novo Nordisk reported significant reductions in HbA1c and body weight with its investigational once-weekly therapy CagriSema across three phase 3…

editorial2 weeks ago

0 0

Johnson & Johnson to buy Firefly Bio for $1 billion to strengthen cancer pipeline

The acquisition brings Firefly Bio’s proprietary Firelink™ degrader antibody conjugate platform into Johnson & Johnson’s oncology portfolio, expanding its focus…